Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodulin in Severe Community Acquired Pneumonia
NCT01420744Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Aug 2011
- Primary completion
- Feb 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Community-acquired pneumonia (CAP) comparing Trimodulin Arm with Placebo Arm (2 arms). Primary endpoint: Ventilator Free Days at 28 days. Started Aug 2011; status: completed.
02
Drugs
Pentaglobin
03
Conditions
Community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT01420744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01420744.